Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Moulin

Showing results (131-140 of 165) with videos related to

Pageof 17
Sort By:
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 12, 2009
Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trialPedro A Lemos, Bruno Moulin, Marco A Perin, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|May 27, 2010
Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trialJacques Dantal, François Berthoux, Marie-Christine Moal, et al.
Arquivos Brasileiros De Cardiologia|April 10, 2010
Rationale and design for the PAINT randomized trialPedro A Lemos, Bruno Moulin, Marco A Perin, et al.
Transplantation|July 9, 2009
Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimusLaetitia Albano, François Berthoux, Marie-Christine Moal, et al.
Cardiovascular Diagnosis and Therapy|January 23, 2015
Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAINT trialJulio F Marchini, Wilton F Gomes, Bruno Moulin, et al.
Clinical Transplantation|May 10, 2007
Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplantGeorges Mourad, Alexandre Karras, Nassim Kamar, et al.
Transplantation|September 21, 2012
The Seville expert workshop for progress in posttransplant lymphoproliferative disordersDenis Glotz, Jeremy R Chapman, Vikas R Dharnidharka, et al.
Transplantation|October 3, 2020
Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant RecipientsIlies Benotmane, Peggy Perrin, Gabriela Gautier Vargas, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2017
A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative DisordersSophie Caillard, Etienne Cellot, Jacques Dantal, et al.
Frontiers in Immunology|September 3, 2019
End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal TransplantationClémence Carron, Jean-Paul Pais de Barros, Emilie Gaiffe, et al.
Pageof 17

Showing results (131-140 of 165) with videos related to

Sort By:
Pageof 17
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 12, 2009
Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trialPedro A Lemos, Bruno Moulin, Marco A Perin, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|May 27, 2010
Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trialJacques Dantal, François Berthoux, Marie-Christine Moal, et al.
Arquivos Brasileiros De Cardiologia|April 10, 2010
Rationale and design for the PAINT randomized trialPedro A Lemos, Bruno Moulin, Marco A Perin, et al.
Transplantation|July 9, 2009
Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimusLaetitia Albano, François Berthoux, Marie-Christine Moal, et al.
Cardiovascular Diagnosis and Therapy|January 23, 2015
Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAINT trialJulio F Marchini, Wilton F Gomes, Bruno Moulin, et al.
Clinical Transplantation|May 10, 2007
Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplantGeorges Mourad, Alexandre Karras, Nassim Kamar, et al.
Transplantation|September 21, 2012
The Seville expert workshop for progress in posttransplant lymphoproliferative disordersDenis Glotz, Jeremy R Chapman, Vikas R Dharnidharka, et al.
Transplantation|October 3, 2020
Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant RecipientsIlies Benotmane, Peggy Perrin, Gabriela Gautier Vargas, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2017
A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative DisordersSophie Caillard, Etienne Cellot, Jacques Dantal, et al.
Frontiers in Immunology|September 3, 2019
End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal TransplantationClémence Carron, Jean-Paul Pais de Barros, Emilie Gaiffe, et al.
Pageof 17